A
Adaptive Biotechnologies Corp (ADPT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
$28.49
+0.62 (+2.22%)
Market Cap: $4.70B
Last updated: Nov 17, 2026 at 4:33 PM ET
Adaptive Biotechnologies Corp (ADPT) Valuation Multiples
Adaptive Biotechnologies (ADPT) trades at 15.3x sales and 25.9x book value. Its P/S of 15.3x is above its 5-year median of 7.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 15.3x |
| Price to book | 25.9x |
| PEG | N/A |
| FCF yield | -0.2% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 15.3x | 7.0x | N/A |
| P/B | 25.9x | 3.3x | N/A |
Valuation History
Over the 7 year ends shown, its P/S ranged from 4.2x in 2023 to 81.5x in 2020.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $16.24 | 8.9x | 11.4x |
| 2024 | $6.00 | 4.9x | 4.4x |
| 2023 | $4.90 | 4.2x | 2.3x |
| 2022 | $7.64 | 5.9x | 2.4x |
| 2021 | $28.06 | 25.5x | 6.6x |
| 2020 | $59.13 | 81.5x | 10.9x |
| 2019 | $29.92 | 21.7x | 6.5x |
Frequently Asked Questions About ADPT
What is ADPT's price to sales ratio?
Adaptive Biotechnologies has a price to sales ratio of 15.3x.
ADPT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts